Centessa reports Q3 net loss of $54.9M; ORX750 Phase 2a meets endpoints in NT1, NT2, IH

Centessa Pharmaceuticals plc

2025-Q3 EPS reported -$0.98 revenue$15,000,000

Net loss of $54.9M in Q3 2025 vs $42.6M in Q3 2024; R&D expenses rose to $41.6M.
Cash and investments $349M as of Sep 30, 2025, expected to fund operations into mid-2027.
ORX750 Phase 2a showed statistically significant improvements on MWT, ESS, and cataplexy rate across NT1, NT2, and IH at low doses.
ORX142 Phase 1 demonstrated rapid onset and differentiated PK; patient studies planned for Q1 2026.
Registrational program for ORX750 expected to start Q1 2026; ORX489 IND-enabling studies ongoing.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.